Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 1
2018 2
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. O'Malley DM, et al. Among authors: munley j. Target Oncol. 2023 Jul;18(4):471-503. doi: 10.1007/s11523-023-00970-w. Epub 2023 Jun 3. Target Oncol. 2023. PMID: 37268756 Free PMC article. Review.
Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.
Christian JB, Finkle JK, Ky B, Douglas PS, Gutstein DE, Hockings PD, Lainee P, Lenihan DJ, Mason JW, Sager PT, Todaro TG, Hicks KA, Kane RC, Ko HS, Lindenfeld J, Michelson EL, Milligan J, Munley JY, Raichlen JS, Shahlaee A, Strnadova C, Ye B, Turner JR. Christian JB, et al. Among authors: munley jy. Am Heart J. 2012 Dec;164(6):846-55. doi: 10.1016/j.ahj.2012.09.001. Epub 2012 Oct 26. Am Heart J. 2012. PMID: 23194484 Free PMC article. Review.
Drug-induced myocardial dysfunction - recommendations for assessment in clinical and pre-clinical studies.
Ebrahimi A, Raichlen JS, Pointon A, Gottfridsson C, Munley J, Hockings P, Cartwright J, Buss N, Wikström J, Gan LM, Whittaker A, Khalil A, George RT, Garkaviy P, Brott D. Ebrahimi A, et al. Among authors: munley j. Expert Opin Drug Saf. 2020 Mar;19(3):281-294. doi: 10.1080/14740338.2020.1731471. Epub 2020 Feb 25. Expert Opin Drug Saf. 2020. PMID: 32064957 Review.
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C. Cadoo K, et al. Among authors: munley j. Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5. Gynecol Oncol. 2022. PMID: 35803835 Free PMC article. Clinical Trial.
Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA Jr. Hirsch FR, et al. Among authors: munley j. Cancer. 2018 Jun 1;124(11):2407-2414. doi: 10.1002/cncr.31313. Epub 2018 Mar 26. Cancer. 2018. PMID: 29579334 Free article.